Curadel Surgical Innovations has filed a notice of an exempt offering of securities to raise $57,500,000.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Curadel Surgical Innovations is raising up to $57,500,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Curadel Surgical Innovations
Curadel Surgical Innovations is an audacious innovator in radiopharmaceuticals and optical surgical-navigation drugs, leveraging proprietary zwitterionic technology to pursue better outcomes in cancer treatment and surgery. The companys platform is designed to prevent tumor resistance and regrowth while reducing damage to healthy tissues, with a focus on challenging metastatic cancers. Curadels team includes recognized experts dedicated to addressing the limitations of conventional radiation therapy and improving long-term cancer-survival outcomes. Its lead surgical-navigation drug, ZW800-1 (nizaracianine triflutate), entered the Phase 3 portion of a pivotal study intended to highlight the ureter during abdominopelvic surgery. Curadel also secured $10.5 million in Series A2 funding to advance its novel zwitterionic radiotherapy platform and early-stage programs.

To learn more, visit https://www.curadelpharma.com/
LinkedIn: https://www.linkedin.com/company/curadelpharma/

Contact:
John Frangioni, Chief Executive Officer
https://www.linkedin.com/in/john-frangioni-b0607775/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.